Pleiotropic action of genetic variation in ZNF804A on brain structure: a meta-analysis of magnetic resonance imaging studies

This article was published in the following Dove Medical Press journal:
Neuropsychiatric Disease and Treatment

Shuai Wang^{1,2}

Yi He³

Zi Chen¹

Yanzhang Li¹

Jingping Zhao²

Luxian Lyu⁴

¹Department of Psychology, Chengdu Medical College, Chengdu, People's Republic of China; ²Mental Health Institute of the Second Xiangya Hospital, Central South University, National Clinical Research Center on Mental Health Disorders, National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, People's Republic of China; ³Medical Group, Department of Academic Popularization, DIAO Group, Chengdu, People's Republic of China; ⁴Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China

Objective: The zinc finger protein 804A (*ZNF804A*) gene encodes the protein 804A containing the C2H2 zinc finger structure, which plays an important role in embryonic nerve development and repair. Previous studies have shown a significant association between the *ZNF804A* genetic variation polymorphism rs1344706 and the risk of schizophrenia and brain structure abnormalities. However, the findings are inconsistent.

Materials and methods: Seventeen studies on structural magnetic resonance imaging (sMRI), with 1,031 schizophrenia patients and 3,416 healthy controls, were included in the meta-analysis. These analyses were performed using Anisotropic Effect-Size Signed Differential Mapping (AES-SDM) software and Comprehensive Meta-Analysis (CMA) software.

Results: rs1344706 risk allele carriers of schizophrenia had increased gray matter in the brain regions including frontal lobe, temporal lobe, and other brain regions, but the carriers of healthy individuals had decreased gray matter and white matter integrity in the frontal lobe, central network, and other brain regions. The results of sensitivity analysis are stable, but publication bias exists in a few analyses of indexes.

Conclusion: Abnormalities of brain structure have a strong relationship with *ZNF804A* gene rs1344706 polymorphism, but the association may be different in healthy individuals and those with mental disorders.

Keywords: ZNF804A, genetic variation, magnetic resonance imaging, brain structure, meta-analysis

Introduction

Brain damage can directly lead to mental disorders. Abnormalities in gray matter of the frontal lobe are found in schizophrenia patients.¹ The central nervous system is composed of neurons and glial cells; the former is mainly responsible for the transmission and processing of information, while the latter supports neurons and plays a role in protection, nutrition, and formation of myelin sheath and repair.² Neurons send signals through synaptic connections, and there is approximately one teraflop of brain operation occurring in the synaptic connections, forming a number of neural circuits that underlie mental and neural activity. Once these brain regions are changed, the individual may show noticeable psychiatric symptoms.³⁻⁵

Schizophrenia has a major genetic component, and it is both etiologically and clinically complex. A genome-wide association study found that the single-nucleotide polymorphism rs1344706 of the zinc finger protein 804A (*ZNF804A*) gene is associated with schizophrenia. The alleles of rs1344706 result in differential prediction of the presence of binding sites for two brain-expressed transcription factors. The MYT1L

Correspondence: Shuai Wang
Department of Psychology, Chengdu Medical College, No 783, Xindu Avenue, Chengdu 610000, People's Republic of China
Tel +86 134 0921 5747
Email wshuai86@126.com

zinc finger protein is expressed in neural progenitors along with the related family member MYT1 (which is known to modulate proliferation and terminal differentiation of oligodendrocyte progenitors).⁶ Of note, the *MYT1L* gene was included in a copy number variant observed in an affected individual in a recent study of structural variation in schizophrenia. The POU3F1/Oct-6 POU domain transcription factor is involved in oligodendrocyte differentiation and the transition of promyelinating to myelinating Schwann cells and is also normally expressed in adult cortex and hippocampus.⁶ Researchers use “imaging genetics” to explore the relationship between the risk gene and brain structural changes in patients with mental disorders. Lencz et al⁷ investigated the effect of *ZNF804A*, a risk gene for schizophrenia, on neuroanatomy and neurocognitive phenotypes. They found that healthy individuals with homozygous risk allele T have larger overall white matter and smaller gray matter compared with C allele carriers. This phenotype may directly reflect altered neural connection status. Wassink et al⁸ found that rs1344706 has a significant effect on total, frontal, and parietal white matter content in patients with schizophrenic spectrum diseases and their health.

Although there is a number of evidence to support the influence of the *ZNF804A* gene on the brain structure of healthy individuals and those with mental disorders, they are inconsistent. There is still a lack of meta-analysis to comprehensively evaluate these disparate findings. Therefore, the aim of this study was to explore the relationship between brain structure and the *ZNF804A* gene rs1344706 polymorphism based on a signed difference map. It also provides a reference for studying genetic-related mechanisms of mental disorders such as schizophrenia.

Materials and methods

Study design

The study was designed using voxel-based and general meta-analysis methods based on clinical data of statistical maps, peak coordinates, and statistical effect size collected from previous association studies of brain structural changes and *ZNF804A* gene polymorphisms. Two researchers (SW and YH) independently reviewed the literature and selected studies to use in the meta-analysis. Any disagreement was resolved through a group discussion.

Searching strategies

Literature searches were performed in databases including Medline, ScienceDirect, and Scopus before December 2017. The following search terms were combined and

used: “ZNF804A/rs1344706” and “MRI/structural MRI/sMRI”. Publications from conferences, monographs, theses, or reference lists in identified studies were also regarded as potential sources to be included in the meta-analysis.

Inclusion and exclusion criteria

According to the PRISMA guidelines,⁹ the following criteria were used for inclusion in the meta-analysis: 1) original research published in peer-reviewed journals, conferences, or monographs; 2) scanning methods were structural (structural magnetic resonance imaging, sMRI); 3) studies comparing the brain structure in individuals with different genotypes of rs1344706 in the *ZNF804A* gene; 4) for Anisotropic Effect-Size Signed Differential Mapping (AES-SDM) analysis, the coordinates (either Talairach or Montreal Neurological Institute) of altered brain regions were detailed; 5) for Comprehensive Meta-Analysis (CMA), the effect size of different brain regions was listed as *F*, *t*, *z*, or *P*-values; 6) the publication was in English. Meanwhile, the following studies were excluded: 1) studies with region of interest (ROI) approaches and 2) studies not performed using sMRI. Two researchers (SW and ZC) examined the abstract or full text of all searched articles to identify studies that fit the abovementioned criteria. When multiple studies used the same individual cohort, the one with the largest sample size was selected.

Data extraction and quality scores

Two researchers (SW and YH) independently extracted the basic data, including 1) general characteristics such as first author and year of publication; 2) samples' information such as individuals (schizophrenia or healthy controls), race, sample size, age, and gender; 3) genetic data such as distribution of genotypes and alleles of rs1344706; and 4) imaging data such as tesla of magnetic resonance imaging (MRI) and full width at half-maximum. We also obtained voxel-based data, which included the peak coordinates and effect size of statistically significant differences of brain structure. Missing data were acquired from the corresponding authors of the study by e-mail. If missing data could not be acquired, the studies were excluded. Any disagreement about the data was resolved through group discussions with consensus. All data were checked for internal consistency. The quality of the included studies was evaluated using a checklist that focused on both the clinical and demographic aspects of individual study samples and the imaging-specific methodology used in the studies. We also adopted recently established preprocessing and computational parameters.

AES-SDM analysis

The meta-analysis of sMRI studies was performed using AES-SDM software, which has been previously used in several neuropsychiatric disorders.¹⁰ AES-SDM software is a voxel-based meta-analytic approach that enables the use of reported peak coordinates of gray and white matter difference in whole brain studies.¹¹ The AES-SDM method has been previously described.¹²

Two researchers (SW and YH) performed the meta-analysis. The main threshold was set at uncorrected $P < 0.001$ (empirically equivalent to $P < 0.05$, corrected) with z score > 1 (peak height) and cluster extent ≥ 20 voxels. The default settings in the AES-SDM software were used for other parameters. A leave-one-out jackknife analysis was used to determine the sensitivity of the reported results to the inclusion of individual studies. Heterogeneity among studies was assessed through the Q statistic with a threshold of $P < 0.05$.

CMA

Some studies failed to provide the differential peak coordinates for the AES-SDM analysis. To integrate more data, we further

analyzed the differences of brain structure between *ZNF804A* gene rs1344706 carriers and noncarriers with CMA software. Statistical effect value was set as Z . The heterogeneity of the results was assessed with the I^2 statistic using the chi-squared test at $\alpha = 0.1$. When $I^2 \leq 50\%$, it was considered that there was no heterogeneity, and the fixed-effect model was used for the meta-analysis. Otherwise, the studies were considered to involve significant heterogeneity, and the random-effect model was used. Publication bias was tested using Egger's test. Then, $P < 0.05$ was used to denote statistical significance.

Results

Basic information of included studies

The entire search process is as described in the quorum-type flowchart (Figure 1). Seventeen studies^{7,8,13–27} on brain structure met the inclusion criteria, and one¹⁴ of which involved both gray matter and white matter. The overall sample was equivalent to a cohort of 1,031 schizophrenia patients and 3,416 healthy controls. The general, genotype, and scanning information and quality scores of each study are summarized in Tables 1 and 2.

Figure 1 Flowchart of the selection process.

Table 1 General characteristics of the included studies

Study	Year of publication	Population (n)	Age (years)	Gender (male, n)	Ancestry	Medication	Genotype distribution			
							AA	AC	CC	HWE
Gray matter										
Lencz et al ⁷	2010	HC (39)	34.4	19	Caucasian	–	18	14	7	Yes
Donohoe et al ¹³	2011	SZ (70)	40.4	46	Caucasian	Yes	27	30	13	Yes
		HC (38)	32.5	20	Caucasian	–	19	14	5	Yes
Voineskos et al ¹⁴	2011	HC (62)	37.4	40	Caucasian	–	23	33	6	Yes
Cousijn et al ¹⁵	2012	HC (892)	22.8	369	Caucasian	–	297	434	160	Yes
Wassink et al ⁸	2012	SZ (335)	31.7	248	Caucasian	Yes	126	165	44	NS
		HC (198)	30.7	103	Caucasian	–	69	105	24	NS
Wei et al ¹⁶	2012	SZ (80)	26.6	45	Chinese	Yes	15	46	19	Yes
		HC (69)	25.4	39	Chinese	–	22	35	12	Yes
Bergmann et al ¹⁷	2013	SZ (82)	34.2	49	Caucasian	Yes	NS	NS	NS	NS
		HC (152)	35.9	79	Caucasian	–	NS	NS	NS	NS
Schultz et al ¹⁸	2014	SZ (55)	29.3	NS	Caucasian	Yes	20	35 (AC + CC)		NS
		HC (40)	27.3	NS	Caucasian	–	15	25 (AC + CC)		NS
Cousijn et al ²⁰	2015	HC (1,300)	22.9	43	Caucasian	–	NS	NS	NS	NS
Nenadic et al ¹⁹	2015	SZ (62)	31.6	44	Caucasian	Yes	23	33	6	Yes
		HC (54)	29.5	29	Caucasian	–	19	28	7	Yes
Wei et al ²¹	2015	SZ (59)	26.3	31	Chinese	No	26	16	17	Yes
		HC (60)	25.6	33	Chinese	–	38	12	10	Yes
White matter										
Voineskos et al ¹⁴	2011	HC (62)	37.4	40	Caucasian	–	23	33	6	Yes
Kuswanto et al ²²	2012	SZ (125)	34.3	90	Chinese	Yes	26	53	32	Yes
		HC (75)	31.9	48	Chinese	–	11	37	19	Yes
Sprooten et al ²³	2012	HC (50)	22.7	25	Caucasian	–	19	24	7	Yes
Wei et al ²⁴	2013	SZ (100)	26.5	53	Chinese	Yes	18	58	24	Yes
		HC (69)	25.4	39	Chinese	–	22	35	12	Yes
Ikuta et al ²⁵	2014	HC (107)	31.8	56	Caucasian	–	43	42	22	NS
Mallas et al ²⁶	2016	SZ (63)	33.8	50	Mixed	Yes	27	28	8	Yes
		HC (124)	35.8	67	Mixed	–	59	51	14	Yes
Zhang et al ²⁷	2016	HC (87)	27.6	68	Chinese	–	23	43	21	Yes

Abbreviations: HC, healthy control; SZ, schizophrenia.

Table 2 Scanning characteristics and quality assessment of the included studies

Study	Year of publication	fMRI information				Quality
		Tesla	FWHM (mm)	Task	Indices	
Gray matter						
Lencz et al ⁷	2010	1.5	NS	None	GM, WM, CSF	High
Donohoe et al ¹³	2011	1.5	8	None	GM	High
Voineskos et al ¹⁴	2011	1.5	NS	None	CT	High
Cousijn et al ¹⁵	2012	1.5, 3.0	8	None	GM, WM	High
Wassink et al ⁸	2012	1.5	NS	None	GM, WM, CSF	High
Wei et al ¹⁶	2012	1.5	12	None	WM	High
Bergmann et al ¹⁷	2013	1.5	30	None	CT	Medium
Schultz et al ¹⁸	2014	1.5	NS	None	CT, CF	Medium
Cousijn et al ²⁰	2015	1.5	NS	None	GM, WM	Medium
Nenadic et al ¹⁹	2015	1.5	12	None	GM, WM	High
Wei et al ²¹	2015	1.5	10	None	CT, CSA, CV	High
White matter						
Voineskos et al ¹⁴	2011	1.5	None	None	FA	High
Kuswanto et al ²²	2012	3	None	None	FA	High
Sprooten et al ²³	2012	1.5	None	None	FA, MD	High
Wei et al ²⁴	2013	1.5	None	None	FA, MD	High
Ikuta et al ²⁵	2014	3	None	None	FA	High
Mallas et al ²⁶	2016	1.5	None	None	FA	High
Zhang et al ²⁷	2016	3	None	None	FA	High

Abbreviations: fMRI, functional magnetic resonance imaging; FWHM, full width at half-maximum; NS, not stated; GM, gray matter; WM, white matter; CSF, cerebrospinal fluid; CT, cortical thickness; CF, cortical fold; CSA, cortical surface area; CV, cortical volume; FA, fractional anisotropy; MD, mean diffusivity.

Table 3 Influence of *ZNF804A* rs1344706 on gray matter (AES-SDM)

Brain region	Peak coordinate					Cluster	
	MNI (x, y, z)			SDM-z	P-value	Voxels	Breakdown (voxels)
Positive effects of rs1344706 risk alleles in HC							
None							
Negative effects of rs1344706 risk alleles in HC							
Left superior temporal gyrus	−60	26	10	−2.299	0.00027	252	BA21 (93) BA22 (89) BA22 (25) Corpus callosum (18) BA23 (29)
Left median network, cingulum	−4	−22	34	−1.949	0.00076	52	BA23 (29)
Positive effects of rs1344706 risk alleles in SZ							
Right inferior frontal gyrus	44	22	−12	2.634	0.00019	248	BA38 (102) BA47 (52) BA48 (29) BA48 (13)
Left superior temporal gyrus	−54	−6	6	2.479	0.00033	83	BA48 (59) BA48 (17)
Negative effects of rs1344706 risk alleles in SZ							
None							

Abbreviations: AES-SDM, Anisotropic Effect-Size Signed Differential Mapping; MNI, Montreal Neurological Institute.

Significant genetic–neuroimaging associations in AES-SDM

Six studies on gray matter containing peak coordinates were included in this part of AES-SDM analysis. For healthy controls, rs1344706 risk allele carriers had decreased gray matter in the left superior temporal gyrus ($z=-2.299$, $P=0.00027$) and left median network ($z=-1.949$, $P=0.00076$) compared with noncarriers. However, for schizophrenia patients, the risk allele carriers had increased gray matter in the right inferior frontal gyrus ($z=2.634$, $P=0.00019$) and left superior temporal gyrus ($z=2.479$, $P=0.00033$) compared with noncarriers. The AES-SDM results of gray matter are summarized in Table 3 and Figure 2.

Two studies on white matter containing peak coordinates were included in this part of AES-SDM analysis. For healthy

controls, rs1344706 risk allele carriers had decreased white matter integrity in the left median network ($z=-1.100$, $P=0.00005$) and corpus callosum ($z=-1.099$, $P=0.00005$) compared with noncarriers. However, no study involved schizophrenia patients. The AES-SDM results of white matter are summarized in Table 4 and Figure 3.

Significant genetic–neuroimaging associations in CMA

Seventeen studies containing effect sizes were included in the CMA analysis. For healthy controls, rs1344706 risk allele carriers had decreased gray matter in the frontal ($z=-2.008$, $P=0.045$), temporal ($z=-6.099$, $P=0.000$), and occipital ($z=-3.106$, $P=0.002$) areas compared with noncarriers. However, for schizophrenia patients, the risk allele carriers had increased gray matter in the frontal ($z=3.445$, $P=0.001$), temporal ($z=2.140$, $P=0.032$), parietal ($z=5.346$, $P=0.000$), occipital ($z=3.605$, $P=0.000$), limbic system ($z=4.765$, $P=0.000$), and basal nucleus ($z=4.689$, $P=0.000$) areas compared with noncarriers. In addition, there was no difference in white matter between the rs1344706 risk allele carriers and noncarriers in both patients and healthy individuals. The CMA results are summarized in Table 5.

Figure 2 AES-SDM results of the effect of risk allele on gray matter.

Notes: Regions highlighted in red signify increased gray matter in schizophrenia patients carrying risk allele compared with noncarriers. Regions highlighted in blue signify decreased gray matter in healthy individuals carrying risk allele compared with noncarriers.

Abbreviation: AES-SDM, Anisotropic Effect-Size Signed Differential Mapping.

Discussion

In this meta-analysis, AES-SDM software and CMA software were used to integrate the 17 studies and determine the association between *ZNF804A* gene rs1344706 polymorphism and brain structure. The present study not only analyzed

Table 4 Influence of *ZNF804A* rs1344706 on white matter (AES-SDM)

Brain region	Peak coordinate					Cluster size in voxels
	MNI (x, y, z)			SDM-z	P-value	
Positive effects of rs1344706 risk alleles						
None						
Negative effects of rs1344706 risk alleles						
Left median network, cingulum	−16	42	8	−1.100	0.00005	59
Corpus callosum	2	8	24	−1.099	0.00005	52
	20	−42	36	−1.101	0.00001	45

Abbreviations: AES-SDM, Anisotropic Effect-Size Signed Differential Mapping; MNI, Montreal Neurological Institute.

mental disorders with schizophrenia but also included healthy individuals. In the AES-SDM analysis, only a part of the eligible studies were included due to the limitations of peak coordinates in the original literature. We found that schizophrenia patients carrying the risk allele of rs1344706 in *ZNF804A* had a larger gray matter in the right inferior frontal gyrus and the left superior temporal gyrus compared with noncarriers. Conversely, healthy controls with risk alleles had a smaller gray matter in the left superior temporal gyrus and left median network. It is important to note that the risk allele of rs1344706 has a completely opposite effect on the left superior temporal gyrus in different populations. In terms of white matter, the AES-SDM meta-analysis concluded that the white matter integrity was lower in healthy

controls carrying the risk allele of rs1344706, including the left median network and corpus callosum compared with noncarriers. However, for schizophrenia patients, there are not enough data to conduct this meta-analysis.

To further verify the association, we then analyzed the included studies using the CMA method. This method allows more data (effect size) to be entered in the meta-analysis, but it cannot determine the precise brain area. The final result suggests that the risk allele of rs1344706 carriers in healthy controls had a smaller gray matter in the frontal and temporal lobes. Conversely, for schizophrenia patients, the risk allele carriers had larger gray matter in the frontal lobe, temporal lobe, parietal lobe, occipital lobe, limbic system, and basal nuclei. These results were basically consistent with those obtained using the AES-SDM method. However, the results of CMA did not suggest that the rs1344706 risk allele had any significant association with the white matter.

Compared with previous reports, the results of this meta-analysis are basically consistent with most of the studies. However, the results of the study by Wei et al²¹ showed that the risk allele had negative effects on brain structure (including cortical thickness, surface area, and volume) in schizophrenia patients. On the contrary, positive effects were found in healthy controls. Similarly, Voineskos et al¹⁴ believed that the risk allele of rs1344706 plays a positive role on the gray matter in healthy controls. In addition, Wassink et al⁸ found that the risk allele of rs1344706 had negative effects on brain structure in both healthy controls and schizophrenia patients. We speculated that the differences might come from the different baselines of the included samples. Furthermore, the ethnic difference of the subjects might contribute to the discriminate distribution frequency of rs1344706 allele and further affected the results of association studies.

The prevailing results of our meta-analysis and previous studies showed that the risk allele of rs1344706 in *ZNF804A* had opposite effects on the brain structure in mental disorders

Figure 3 AES-SDM results of the effect of risk allele on white matter.

Note: Regions highlighted in blue signify decreased white matter integrity in healthy individuals carrying risk allele compared with noncarriers.

Abbreviation: AES-SDM, Anisotropic Effect-Size Signed Differential Mapping.

Table 5 Influence of *ZNF804A* rs1344706 on brain structure (CMA)

Indices	Region	Population	Model	Effect size				Heterogeneity		Egger's regression intercept		Publication bias
				Z	P-value	D	95% CI	I ²	P-value	T	P-value	
Gray matter	Frontal	HC	Random	-2.008	0.045	-0.740	-1.463--0.018	89.022	0.000	15.644	0.004	Yes
		SZ	Fixed	3.445	0.001	0.778	0.336--1.221	60.166	0.057	1.185	0.358	No
	Temporal	HC	Fixed	-6.099	0.000	-0.958	-1.266--0.650	17.898	0.301	2.967	0.097	No
		SZ	Random	2.140	0.032	0.302	0.025--0.579	89.678	0.000	0.120	0.916	No
White matter	Parietal	SZ	Fixed	5.346	0.000	1.124	0.712--1.537	0.000	0.923	-	-	-
		HC	Fixed	-3.106	0.002	-0.631	-1.030--0.233	33.581	0.220	-	-	-
	Occipital	SZ	Fixed	3.605	0.000	0.748	0.342--1.155	54.182	0.140	-	-	-
		HC	Random	-1.485	0.138	-0.900	-2.087--0.288	93.838	0.000	11.921	0.053	No
White matter	Limbic system	SZ	Fixed	4.765	0.000	0.939	0.553--1.325	0.000	0.631	-	-	-
		SZ	Fixed	4.689	0.000	0.952	0.554--1.350	0.000	0.869	-	-	-
	Basal nuclei	HC	Random	0.081	0.936	0.018	-0.430--0.467	80.609	0.000	1.325	0.256	No
		SZ	Random	-0.295	0.768	-0.087	-0.667--0.492	79.300	0.008	4.468	0.140	No

Abbreviations: CMA, Comprehensive Meta-Analysis; HC, healthy control; SZ, schizophrenia.

such as schizophrenia (positive) and healthy individuals (negative). It may be due to different genetic variations or genetic environment in subjects.^{28,29} For example, Guella et al³⁰ found that the A allele of rs12476147 in exon 4 of *ZNF804A* is overexpressed in the dorsolateral prefrontal cortex of individuals heterozygous for rs1344706. Furthermore, this allele of rs12476147 could increase the risk of schizophrenia. In the same study, the risk allele of rs1344706 was found to be a cis-regulatory variant that could directly lead to an imbalance of this allele expression in adult cerebral cortex.³⁰ Therefore, the different effects of rs1344706 on schizophrenia patients and healthy individuals may be related to the neuropathological mechanism of this risk variant. The increased gray matter in risk allele carriers may give the suggestion of the risk allele participation in schizophrenia and the brain changes of the patients.

Imaging genetic study is generally designed to assess the impact of specific risk genes (or risk scores) on brain structure. However, it is unclear how gene expression or gene products affect the brain structure and function. Several variants have been forthcoming in schizophrenia, in particular *ZNF804A*, located in the major histocompatibility complex. The strongest support is *ZNF804A*, encoding a zinc finger protein of unknown, but possibly regulatory function.³¹ An increasing number of evidence shows that the genetic effect on the brain begins at the early stages of neural development.³² The rs1344706 polymorphism affects the expression of *ZNF804A* in the brain during embryonic development, but this effect does not exist in the adult brain.³² However, autopsy studies found that *ZNF804A* expression is different in schizophrenia patients and healthy controls.^{33,34} These findings directly or indirectly demonstrate that there is a relationship between *ZNF804A* expression and brain development. However, the mechanisms of a given polymorphism impacting specific brain regions need further exploration.

Finally, the present meta-analysis has heterogeneity and publication bias in the discussion of some indicators. The greatest source of heterogeneity may come from the studies with opposite data. In addition, differences in the scan parameters and analytical indicators may also increase the heterogeneity. The trim and fill processes did not change the general result (although the strength of the association was slightly attenuated), suggesting that the association is not an artifact of unpublished negative studies. Nevertheless, that possibility is not fully excluded by this method. The unpublished articles in other languages have not been included in this meta-analysis and may result in publication bias. In general, the meta-analysis further confirmed the influence of the risk allele of *ZNF804A* gene rs1344706 on the brain

structure and provided further insight into the genetic-related pathogenesis of psychiatric disorders such as schizophrenia.

Conclusion

Abnormalities on brain structure have a strong relationship with *ZNF804A* gene rs1344706 polymorphism, but the association may be different in healthy individuals and those with mental disorders. The risk allele of rs1344706 has a positive effect on brain structure in schizophrenia patients. However, this allele has a negative effect on brain structure in healthy individuals.

Acknowledgments

This study was supported by grants from the Natural Science Foundation of Chengdu Medical College (grant no. CYZ18-08).

Disclosure

The authors report no conflicts of interest in this work.

References

- Shad MU, Keshavan MS. Neurobiology of insight deficits in schizophrenia: an fMRI study. *Schizophr Res*. 2015;165(2–3):220–226.
- Maria BL, Neufeld JA, Rosainz LC, et al. Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression. *J Child Neurol*. 1998;13(12):606–618.
- Brosch T, Neumann H. Computing with a canonical neural circuits model with pool normalization and modulating feedback. *Neural Computation*. 2014;26(12):2735–2789.
- Hopfield JJ, Tank DW. Computing with neural circuits: a model. *Science*. 1986;233(4764):625–633.
- Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. *Br J Psychiatry*. 1991;158(03):340–345.
- Riley B, Thiselton D, Maher BS, et al. Replication of association between schizophrenia and ZNF804A in the Irish case-control study of schizophrenia sample. *Mol Psychiatry*. 2010;15(1):29–37.
- Lencz T, Szeszko PR, Derosse P, et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. *Neuropsychopharmacology*. 2010;35(11):2284–2291.
- Wassink TH, Epping EA, Rudd D, et al. Influence of ZNF804A on brain structure volumes and symptom severity in individuals with schizophrenia. *Arch Gen Psychiatry*. 2012;69(9):885–892.
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):1.
- Xiao B, Wang S, Liu J, Meng T, He Y, Luo X. Abnormalities of localized connectivity in schizophrenia patients and their unaffected relatives: a meta-analysis of resting-state functional magnetic resonance imaging studies. *Neuropsychiatr Dis Treat*. 2017;13:467–475.
- Radua J, Mataix-Cols D, Phillips ML, et al. A new meta-analytic method for neuroimaging studies that combines reported peak coordinates and statistical parametric maps. *Eur Psychiatry*. 2012;27(8):605–611.
- Radua J, Mataix-Cols D. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. *Br J Psychiatry*. 2009;195(5):393–402.
- Donohoe G, Rose E, Frodl T, et al. ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. *Neuroimage*. 2011;54(3):2132–2137.
- Voineskos AN, Lerch JP, Felsky D, et al. The ZNF804A gene: characterization of a novel neural risk mechanism for the major psychoses. *Neuropsychopharmacology*. 2011;36(9):1871–1878.
- Cousijn H, Rijpkema M, Hartevelde A, et al. Schizophrenia risk gene ZNF804A does not influence macroscopic brain structure: an MRI study in 892 volunteers. *Mol Psychiatry*. 2012;17(12):1155–1157.
- Wei Q, Kang Z, Diao F, et al. Association of the ZNF804A gene polymorphism rs1344706 with white matter density changes in Chinese schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;36(1):122–127.
- Bergmann Ørjan, Haukvik UK, Brown AA. ZNF804A and cortical thickness in schizophrenia and bipolar disorder. *Psychiatry Research: Neuroimaging*. 2013;212(2):154–157.
- Schultz CC, Nenadic I, Riley B. ZNF804A and cortical structure in schizophrenia: in vivo and postmortem studies. *Schizophrenia bull*. 2014;40(3):532–541.
- Nenadic I, Maitra R, Basmanav FB, et al. ZNF804A genetic variation (rs1344706) affects brain grey but not white matter in schizophrenia and healthy subjects. *Psychol Med*. 2015;45(1):143–152.
- Cousijn H, Tunbridge EM, Rolinski M, et al. Modulation of hippocampal theta and hippocampal-prefrontal cortex function by a schizophrenia risk gene. *Hum Brain Mapp*. 2015;36(6):2387–2395.
- Wei Q, Li M, Kang Z, et al. ZNF804A rs1344706 is associated with cortical thickness, surface area, and cortical volume of the unmedicated first episode schizophrenia and healthy controls. *Am J Med Genet*. 2015;168(4):265–273.
- Kuswanto CN, Woon PS, Zheng XB, et al. Genome-wide supported psychosis risk variant in ZNF804A gene and impact on cortico-limbic WM integrity in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2012;159B(3):255–262.
- Sprooten E, McIntosh AM, Lawrie SM, et al. An investigation of a genomewide supported psychosis variant in ZNF804A and white matter integrity in the human brain. *Magn Reson Imaging*. 2012;30(10):1373–1380.
- Wei Q, Kang Z, Diao F, et al. No association of ZNF804A rs1344706 with white matter integrity in schizophrenia: a tract-based spatial statistics study. *Neurosci Lett*. 2013;532:64–69.
- Ikuta T, Peters BD, Guha S, et al. A schizophrenia risk gene, ZNF804A, is associated with brain white matter microstructure. *Schizophr Res*. 2014;155(1–3):15–20.
- Mallas E-J, Carletti F, Chaddock CA, et al. Genome-wide discovered psychosis-risk gene ZNF804A impacts on white matter microstructure in health, schizophrenia and bipolar disorder. *PeerJ*. 2016;4(10):e1570.
- Zhang Z, Chen X, Yu P, et al. Effect of rs1344706 in the ZNF804A gene on the connectivity between the hippocampal formation and posterior cingulate cortex. *Schizophr Res*. 2016;170(1):48–54.
- Prata DP, Mechelli A, Fu CHY, et al. Epistasis between the DAT 3'UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. *Proc Natl Acad Sci U S A*. 2009;106(32):13600–13605.
- Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with Nrg1, ErbB4, and Akt1 epistasis via functional neuroimaging in healthy controls. *Arch Gen Psychiatry*. 2010;67(10):991–1001.
- Guella I, Sequeira A, Rollins B, et al. Evidence of allelic imbalance in the schizophrenia susceptibility gene ZNF804A in human dorsolateral prefrontal cortex. *Schizophr Res*. 2014;152(1):111–116.
- Meyer-Lindenberg A. Imaging genetics of schizophrenia. *Dialogues Clin Neurosci*. 2010;12(4):449–456.
- Hill MJ, Bray NJ. Evidence that schizophrenia risk variation in the ZNF804A gene exerts its effects during fetal brain development. *Am J Psychiatry*. 2012;169(12):1301–1308.
- Okada T, Hashimoto R, Yamamori H, et al. Expression analysis of a novel mRNA variant of the schizophrenia risk gene ZNF804A. *Schizophr Res*. 2012;141(2–3):277–278.
- Buonocore F, Hill MJ, Campbell CD, et al. Effects of cis-regulatory variation differ across regions of the adult human brain. *Hum Mol Genet*. 2010;19(22):4490–4496.

Neuropsychiatric Disease and Treatment**Dovepress****Publish your work in this journal**

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>